Conclusions
OSA
SLEEP APNEA
We demonstrate for the first time that the combination of the noradrenergic drug reboxetine and the anticholinergic drug oxybutynin could safely be administrated in OSA patients, who are typically characterized by sympathetic overactivity due to sleep apnea 